Some embrace baldness, while others promote treatments like minoxidil and finasteride. Opinions differ on accepting baldness versus pursuing hair regrowth.
The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.
User is using topical Minoxidil (100 mg/day) and Finasteride (1 mg/day) but experiencing hair growth everywhere except the top of the scalp. They seek advice on improving scalp hair regrowth.
A 30-year-old man with hairline recession is considering using 1% Clascoterone cream on his hairline while awaiting a 5% Breezula product. He has been using oral Minoxidil for four years but stopped using Finasteride due to side effects.
A user is experiencing hair loss at NW 5 and is using finasteride, which is causing side effects like dry eyes and loss of libido. They are considering continuing with minoxidil and finasteride or opting for a hair transplant, feeling depressed about their situation.
The user has experienced significant hair regrowth using finasteride, oral minoxidil, microneedling, keto shampoo, an LLLT helmet, vitamins, and supplements. They note progress but hope for further improvement in a specific area.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
The conversation humorously discusses hair loss treatments, mentioning multiple hair transplants, oral minoxidil, and dutasteride, but not Breezula. It also jokes about the high cost and mild effectiveness of certain treatments.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.